Chemical validation of GPI biosynthesis as a drug target against African sleeping sickness

Terry K. Smith, Arthur Crossman, John S. Brimacombe, Michael A. J. Ferguson

    Research output: Contribution to journalArticle

    56 Citations (Scopus)

    Abstract

    It has been suggested that compounds affecting glycosylphosphatidylinositol (GPI) biosynthesis in bloodstream form Trypanosoma brucei should be trypanocidal. We describe cell-permeable analogues of a GPI intermediate that are toxic to this parasite but not to human cells. These analogues are metabolized by the T. brucei GPI pathway, but not by the human pathway. Closely related nonmetabolizable analogues have no trypanocidal activity. This represents the first direct chemical validation of the GPI biosynthetic pathway as a drug target against African human sleeping sickness. The results should stimulate further inhibitor design and synthesis and encourage the search for inhibitors in natural product and synthetic compound libraries.
    Original languageEnglish
    Pages (from-to)4701-4708
    Number of pages8
    JournalThe EMBO Journal
    Volume23
    Issue number23
    DOIs
    Publication statusPublished - Nov 2004

    Keywords

    • De-N-acetylase
    • Glycosylphosphatidylinositols
    • Inositol acyltransferase
    • Mannosyltransferase
    • Trypanosoma

    Fingerprint Dive into the research topics of 'Chemical validation of GPI biosynthesis as a drug target against African sleeping sickness'. Together they form a unique fingerprint.

  • Cite this